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1. Introduction
Metalloproteinases (MMPs) are a numerous group of proteolytic enzymes whose activity de‐
pends on Zn2+ and Ca2+ ions [1-2]. They participate in various physiological and pathological
processes. They are engaged in the processes of restructuring and degradation of the basement
membrane and components of the extracellular matrix (ECM) [3]. So far, 25 enzymes from that
group have been characterized (22 in humans), as well as 4 their inhibitors (tissue inhibitors of
metalloproteinases - TIMPs) [4-5]. Gene expression of metalloproteinases occurs in almost all
cells: in fibroblasts, keratinocytes, macrophages, endothelium cells, Langerhans dendritic cells,
neurons, microglial cells, myocytes, as well as in inflammatory infiltration cells: in monocytes, T
lymphocytes [5]. Increased activity of metalloproteinases can be observed in various pathologi‐
cal states, i.e. in neoplastic growths, arthritis, periodontal diseases, atherosclerosis, dilated car‐
diomyopathy, myocardial infarction and diseases of the skin [6]. In case of neoplasms, a
possible dependence is often mentioned: quantity and activity level of these enzymes can influ‐
ence advancement of the tumour. Results of many studies show importance of the expression
profile of various MMPs and their inhibitors on the prognosis and course of the disease [7]. Gen‐
erally, changes in proportion of particular MMPs in the whole MMP pool negatively influence
the prognosis. However, in some cases, like e.g. in colorectal cancer, changes in the expression
profile due to increased expression of MMP-12 and MMP-9 are connected with longer surviva‐
bility of the patient and decreased ability of neoplastic cells to cause metastasis [8, 9]. Studies on
the amount of inhibitors metalloproteinase matrices (TIMPs) have proven that there is a rela‐
tion between a high level of TIMP-1 and -2, and an unfavourable prognosis for the patient. The
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cause of an increase in concentration of TIMPs is probably higher expression of MMPs and an at‐
tempt to maintain an equilibrium between MMP and TIMP expression in a neoplastic process
[7]. TIMPs may also favour neoplastic progression through inhibition of apoptosis of neoplastic
cells (TIMP-1 and -2), stimulation of their growth (TIMP-2 and -3) or participation in the begin‐
ning of angiogenesis in a tumour (stimulation of VEGF secretion – TIMP-1) [10]. Moreover,
TIMPs show activity independent from MMPs, e.g. they cause increased levels of anti-apoptot‐
ic protien BCL-XL [11] and have an influence similar to the growth factor [12]. Tests performed
on animals also proved that TIMP-2, despite its name, is an important activator of MMP-2 [13].
1.1. Participation and role of MMPs in the course of a neoplastic process
There  are  six  basic  changes  in  the  physiology  of  a  cell  which  underlie  neoplastic  de‐
velopment [14]:
• self-delivery of signals that stimulate growth,
• lack of sensitivity to signals that inhibit growth,
• escape from apoptosis,
• unlimited proliferation,
• stimulation of angiogenesis,
• invasiveness and ability to create metastasis.
The studies conducted in the last few years confirmed participation of metalloproteinases in
several stages of neoplastic development.
1.1.1. MMPs and regulation of growth of tumour cells
Three ways in which MMPs contribute to proliferation of tumour cells are known. Firstly,
MMPs release precursors of some growth factors, such as e.g. TGF-α [15] that are related to
the cell membrane. Secondly, MMPs may participate in the process of activation of those
factors, e.g. MMP-24 and MMP-25 activate IGF factors (insulin-like growth factors) through
proteolysis of IGF-BPs (insulin-like growth factor binding proteines). Thirdly, metalloprotei‐
nases influence composition of ECM and thus can indirectly regulate proliferation signals
through integrins [16]. MMPs can also influence, in a negative way, growth of neoplastic cells
through TGF-β or through participation in production of proapoptotic factors such as Fas
ligand (FasL) or TNF-α [7].
1.1.2. MMPs and regulation of apoptosis
MMPs demonstrate both apoptotic and anti-apoptotic activity. MMP-3, -7, -9 and MMP-11 are
metalloproteinases with particular significance attributed to them. It was proved that overex‐
pression of MMP-3 in epithelial cells of mammals induce apoptosis, which is probably a result
of laminin degradation [17-19], while MMP-7 can release cell membrane-related FasL – trans‐
membrane stimulator of the FasL death receptor. Released FasL can induce apoptosis of neigh‐
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bouring cells or cause inhibition of neoplastic cells [20-21]. MMP-7 may also inhibit apoptosis
through digestion of pro-HB-EGF (inactive form of the heparin-binding epithelial growth fac‐
tor) and secretion of mature HB-EGF which support cell survival [22]. Anti-apoptotic influence
of MMP-11 is often described with an example of IGFs (insulin-like growth factors) release,
which can be factors that increase survivability of cells [23-24]. During apoptosis of endotheli‐
um, metalloproteinases also participate in digestion of VE-cadherin (vascular endothelial cad‐
herin) [25] and cell adhesion molecules such as: PECAM-1 (a cell adhesion molecule from the
immunoglobulin superfamily) and E-cadherin (epithelial cadherin). Degradation of the afore‐
mentioned cell adhesion molecules may be a cause for typical rounding of apoptotic cells [26].
1.1.3. MMPs and regulation of angiogenesis
An important factor in the growth of a tumour is creation of new blood vessels within its region
[14]. Metalloproteinases play an important role as positive regulators of that process. Tests
conducted on animals have proven that both endogeneous and synthetic inhibitors of metal‐
loproteinases cause decreased angiogenesis [27]. Huge significance is here attributed to the
following metalloproteinases: MMP-2, -9, -14, which directly influence the course of the
angiogenic process, and MMP-19, which is expressed in blood vessel cells [28]. In case of
MMP-2 overexpression, a development of a mysterious feature of αvβ-integrin was described
within type-IV collagen. Blocking that spot with antibodies inhibits migration of endothelial
cells in the process of in vitro angiogenesis and limits growth of the tumour [29]. MMP-9 causes
higher availability of pro-angiogenic VEGF factor, however the mechanism of its action has
not yet been explained [30]. It is believed that also MMP-14 contributes to the angiogenesis of
the tumour as antibodies aimed at the catalytic domain of MMP-14 inhibit migration of
endothelial cells, as well as invasiveness and creation of capillary vessels in vitro [31]. MMP-14
can also degrade fibrillary matrix which surrounds newly created blood vessels, which may
potentially disable endothelial cells to further penetrate the tumour tissue [32]. MMPs also
contribute to creation of molecules which are inhibitors of angiogenesis. Digestion of plasmi‐
nogen by MMP-2, -3, -7, -9 and -12 results in creation of angiostatin [33]. MMP-3, -9, -12, -13
and MMP-20 may also be engaged in creation of endostatin (C-terminal fragment derived from
type XVIII collagen of basement membranes) [34]. Both angiostatin and endostatin reduce
proliferation of endothelial cells [35]. Additionally, endostatin may inhibit invasiveness of
endothelial cells, acting as MMP-14 and MMP-2 inhibitor [36]. MMP-12 may also inhibit
angiogenesis of the tumour through digestion and cutting off the receptor related to the cell
membrane, that is urokinase-type plasminogen activator (u-PA), which is necessary in the
process of invasion of endothelial cells into a fibrin matrix [37].
1.1.4. MMPs and invasiveness and metastasis
During metastasis, neoplastic cells have to overcome several barriers put in their way by ECM.
Firstly, they have to get through the basement membrane of the endothelium and infiltrate the
surrounding stroma. Then they have to infiltrate the blood or lymphatic vessels (intravasation),
migrate through vessel walls to the surrounding tissue (extravasation) and create new,
proliferable metastatic foci [3].
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Digestion of lamina-5 by MMP-2 and MMP-14 contributes to creation of a digestion product,
which facilitates cell movements. Such phenomenon can be observed in experimental in vivo
tumours, while in case of human neoplasms a common location for both MMP-14 and lamina-5
was found [7. However, MMP-14 may also participate in digestion of CD44 receptor (the main
receptor for hyaluronic acid) which resides on the surface of neoplastic cells. That receptor has
an ability to bond MMP-9 and, therefore, attributes to the location of the enzyme on the surface
of the cell. Such location of MMP-9 is necessary to initiate invasion of the tumour cells and
angiogenesis within its boundaries. Therefore, MMP-14 may contribute to a decrease in MMP-9
activity on the surface of the cell, which subsequently may inhibit invasive properties of the
tumour cells and angiogenesis [38].
Progression of the tumour is also connected with disturbance of the functioning of the E-
cadherin cell adhesion molecule, which is digested by MMP-3 and MMP-7. Secretion of an E-
cadherin fragment due to a cut attributes to the invasion of neoplastic cells in the paracrine
way [39]. Digestion of E-cadherin also contributes to transformation of the epithelial cells into
the mesenchymal tissue [40].
During the invasion of tumour cells, placement of metalloproteinases on the cellular invado‐
podia is necessary for them to acquire the ability of invasiveness. MMP-2, -9 and -14 are
metalloproteinases identified as those which appear within the invadopodia, however the
placement mechanisms are different for each of them [41].
Metalloproteinases also participate in late stages of the metastatic process when neoplastic
cells have to intrude blood and lymphatic vessels, survive in them and, finally, evacuate from
them. At that stage, the experimental models describe overexpression of MMP-9 and MMP-14,
which correlates with the growth in number of neoplastic cells which survive in experimental
tests of metastasis [42- 43].
It is believed that there are tissue-specific differences in occurrence of proteinases which initiate
metastasis. Moreover, activity of TIMPs in those tissues, which in some cases inhibit recurrence
of neoplastic foci, also seems to be different [7].
1.1.5. MMPs and immunological response
One of the characteristics of a neoplastic disease is occurrence of inflammatory responses [44].
The immunological system is able to recognize and attack neoplastic cells. However, those
cells have an ability to “escape” supervision and control of the immunological system. Those
phenomena may, to some extend, depend on metalloproteinases [7].
Inflammatory infiltration within a tumour contains cytotoxic T lymphocytes, NK cells and
macrophages which target neoplastic cells. Proliferation of T lymphocytes is regulated by
cytokine signals, precisely by interleukin-2 receptor-α (IL-2Rα) [7].
Metalloproteinases, including MMP-9, can only digest IL-2R and in that way inhibit prolifer‐
ation of T lymphocytes [7]. Metalloproteinases are also an activator of TGF-β [45], an important
T lymphocyte response inhibitor targeted against neoplastic cells [46]. The product of digestion
of 1-proteinase inhibitor created by MMP-11 causes decreased sensitivity of neoplastic cells
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to an attack from NK cells. MMPs may also target the chemokines themselves, which results
in a growth or reduction of infiltration and migration of leukocytes [ADD CITATION]. MMP-9
shows ability to digest neutrophil chemotactic factor CXCL8 (interleukin-8; IL-8), therefore
making it ten times more active. Moreover, MMP-9 inactivates the CXCL7 precursor (a Type-
III connective tissue activating peptide; CTAP-III), CXCL4 (platelet factor 4; PF4) and CXCL1
(growth-related oncogene-α; GROα) [47].
MMP-1, -3, -9, -13, -14 can participate in digestion and inactivation of CXCL12 (stromal cell-
derived factor 1, SDF-1) [48], which is a ligand for the CXCR4 receptor (SDF-1 chemokine
receptor) located on the leukocytes. It is interesting that breast cancer cells also show expression
of CXCR4, while inhibition of binding CXCL12 to CXCR4 through blockage with use of
antibodies significantly reduces in vivo metastasis to lungs and lymph nodes. Therefore,
digestion of CXCL12 by MMPs may inhibit metastasis [49].
Although the immunological system reacts to cancer cells and probably delays progression of
the neoplastic disease, existence of a chronic inflammatory state may also influence develop‐
ment of tumours of the skin, breasts, prostate, ovary, mucous membrane of the stomach, large
intestine, liver and bladder. In progression of neoplastic disease of animal models, inflamma‐
tory cells such as mastocytes, neutrophil granulocyte and macrophages participate in the
process [44]. Those cells synthesize several types of MMPs, including -9, -12 and -14, therefore
release of those MMPs may stimulate neoplastic progression [7].
1.2. Participation of MMPs in progression of melanoma
Melanoma belongs to the group of highly invasive neoplasms with high ability of metastasis
through both blood and lymphatic vessels. Some studies suggest that various arrangements
of proteolytic enzymes play an important role in progression of melanoma. Those include the
plasmin activator system and the extracellular matrix group of metalloproteinases. Melanoma
cells have an ability to produce many kinds of ECM metalloproteinases, including MMP-1, -2,
-9, -13, -14, as well as other inhibitors: TIMP-1, -2, and -3. It is currently believed that metallo‐
proteinases MMP-2 and MMP-9 play the most important roles in development of melanoma.
It was proved that expression and activation of those proteinases is in close relation to the
invasive and metastatic melanoma phenotype [50]. Those metalloproteinases are constitutive‐
ly expressed in the most aggressive forms of melanoma. Their level of expression is strongly
related to the atypia of melanocytes and differentiation of cells within the melanocytic nevi [51].
It was found that in case of both human and mouse melanoma cell lines, increased MMP-2,
MMP-9 and MMP-14 (MT1-MMP) expression is related to an invasive form of the neoplasm
[52]. Increase of MMP-2 is highly related to blood vessel metastasis. Clark's and Breslow's
classification shows relation between a high level of MMP-2 expression and low survivability
index, which is particularly typical for male patients [50]. Studies carried out by Zucker and
Cao [53] proved that MMP-2 is undetectable in situ in human melanoma, however high level
of an active form of that enzyme is present in the matrix of the primary tumour in advanced
stages of melanoma and its metastatic forms. Their results were confirmed by research
conducted by Vaisanen et al. [54], who proved that intensified expression of MMP-2 is a typical
feature of invasive forms of melanoma and is an unfavourable prognostic factor. Increased
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level of MMP-2 expression in mRNA and proteins was also observed in case of the most
aggressive melanoma cell lines (MV3, BLM), as well as xenografts derived from them. The pro-
MMP-2 activation mechanism has not been fully discovered yet. An active form of MMP-2
directly regulates adhesion of melanoma cells and their proliferation to the ECM, facilitating
the processes of migration and invasion [55].
It was also found that increased expression of MMP-14 (MT1-MMP) causes activation of
MMP-2 on the surface of melanoma cells. MMP-2 activity is also regulated by presence of
TIMP-2. On the one hand, an inhibitor may slow down MMP-2 and in that way limit growth
of a tumour and invasion. On the other hand, TIMP-2 may also be directly engaged in activation
of MMP-2 through formation of a complex with MMP-14, which is a receptor for MMP-2 on
the surface of cells. Therefore, co-ordinated expression of MMP-2, MMP-14 and TIMP-2 leads
to activation of MMP-2, while increased concentration of the said metalloproteinases and their
inhibitor is also characteristic for other human neoplasms [50, 55].
The hypothesis that there is a dependence between activation of MMP-2 and overexpression
of MMP-14 was also proved in the research conducted by Kurschat et al. [56]. They found that
in case of abnormal human melanocytes, an increase in expression of both MMP-2 and MMP-14
is related to progression of the neoplasm. An in situ zymographic analysis confirmed presence
of an active form of MMP-2 in the boundary cells of the tumour and in the surrounding matrix.
Moreover, it was proved that the neoplastic cells which produce simultaneously MMP-2 and
MMP-14 are often situated on the boundary between the stroma and the front of the invasive
tumour cells [56].
Tests conducted on mice deprived of MMP-2 gene confirmed that MMP-2 synthesis is
necessary for occurrence of metastasis [50].
Iida et al. [57] found that MMP-14 facilitates invasion of melanoma cells through matrigel,
increases their ability to migrate through lamina-1, facilitates growth of the tumour in in
vitro cell cultures and supports forming of melanoma cell colonies in agarose gel. Moreover,
such influence of MMP-14 which causes increase of invasive abilities of melanoma and
supports growth of the tumour does not depend on the operation of MMP inhibitors [57].
Participation of MMP-9 in progression of melanoma remains unexplained. So far, contradic‐
tory data has only been obtained as to the influence of MMP-9 expression on progression of
melanoma. Experiments conducted on melanoma lines derived from advanced stages of the
neoplasm proved existence of MMP-9 expression. However, no such occurrence was found in
case of cell lines derived from early stages of melanoma [3]. What is more, research carried out
by van den Oord et al. [58] shows that, in case of humans, MMP-9 probably undergoes
expression only in the phase of horizontal growth of the tumour when it does not exceed 1.6
mm in height. No expression of metalloproteinase-9 was found in metastatic material [58].
Nikkola et al. [59] proved that a high level of MMP-9 in blood serum is typical for patients
with vast metastasis and generally shorter survivability time when compared to patients with
lower level of MMP-9 in the serum.
In case  of  experimental  models,  in  which neoplastic  tissue  was  implanted into  rodents,
MMP-9 was identified within the occurring tumour only when its cells were derived from
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advanced melanoma stages [50, 52]. Moreover, in case of organisms that constitutively ex‐
pressed MMP-9, increased colonization of the lungs and metastasis were observed, while
mice without the MMP-9 gene virtually had no secondary neoplastic foci.  Those studies
suggest that MMP-9, which is produced by both neoplastic and stroma cells, plays an im‐
portant  role  in  the  occurrence  of  metastasis.  Moreover,  it  is  thought  that  expression  of
MMP-9 is a feature of neoplastic cells which participate in spontaneous metastasis to the
lymph nodes and lungs. Therefore it seems that the process of selection of the cells which
create in vivo metastasis favours those subclone cells which express MMP-9. As that selec‐
tion is independent from the microenvironment and is not observed during experimental
metastasis, it seems that MMP-9 participates in early stages of metastatic occurrence than
in the later states, such as e.g. extravasation [50, 52].
An important role in the development of melanoma is also attributed to MMP-1 and MMP-3.
Durako et al. [51] proved that gradation of Type-I and Type-IV collagen, as well as invasion
of melanoma cells through matrigel both depend on expression of MMP-1. Nikkola et al. [59]
demonstrated correlation between a high level of MMP-1 and MMP-3 in the tissue and a shorter
survivability time, as well as a relation between expression of MMP-13 and parenchymal
metastases. Increased progression of the neoplastic disease was observed at the beginning of
a therapy in case of patients with higher level of metalloproteinases, while in case of patients
with melanoma, MMP-13 activity was detected [59].
Due to the properties of TIMPs, it seems that an equilibrium between the level of active MMPs
and their inhibitors may be a turning point for neoplastic progression. For example, it was
proved that overexpression of TIMP-1, TIMP-2 and TIMP-3 can cause inhibition of melanoma
invasion. On the other hand, in situ tests show that induction of TIMP-1 and -3 occurs in a late
stage of melanoma tumour progression, which is a result of a complex interaction of the MMP/
TIMP system. Increased expression of TIMPs can also inhibit metastasis, while simultaneously
giving unfavourable prognosis due to TIMPs acting as stimulants to the growth of human
melanoma cells [50].
The studies of Wandel et al. [60] show that stroma cells also participate in induction of the
proteolytic potential of tumour cells. Therefore, expression of MMPs may occur not only in
neoplastic cells but also in the surrounding fibroblasts, which proves participation of those
cells in the process of melanoma progression [50]. Wander et al. [60] proved that both fibro‐
blasts located in the direct vicinity of the in vivo melanoma lesion, as well as those stimulated
with a medium derived from the in vitro culture of melanoma cells (the medium contained
solvable factors secreted by melanoma cells, such as cytokines and growth factors) showed
increased MMP-1 expression of mRNA and proteins. Moreover, a relation between that
phenomenon and invasiveness of the tumour was observed.
As the presented data shows, it seems that ECM metalloproteinases play an important role in
the development of the neoplastic process, including the melanoma tumour. Anomalies in the
expression profile of MMPs not only influence the in situ growth of the tumour itself but
particularly affect location and the way of induction of the metastatic process. This can suggest
that various MMPs may play individual roles in particular stages of melanoma metastasis [52].
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2. Photodynamic therapy in treatment of melanoma
Photodynamic therapy (PDT) is used in treatment of chosen pre-neoplastic states and early
neoplastic stages, as well as for aesthetic and plastic purposes [61]. The basis of PDT is the
interaction of laser light (usually long-wave infrared) with photosensitive molecules selec‐
tively accumulated in pathologically changed tissue, in presence of oxygen. Such interaction
turns those molecules into their cytotoxic forms that, eventually, cause death of the cells,
therefore highly selectively destroying pathological lesion in the tissue [62].
A possibility to use photodynamic therapy in treatment of melanoma is currently a subject of re‐
search conducted on both cell and animal cultures. Photosensitizers and their derivatives, such
as Photofrin, ALA, Porphyrin IX, Vertoporphyrin and others, are currently being assessed or
even used in clinical practice in case of other diseases. Simultaneously, very intensive research
on newly synthesized compounds is being conducted [63 – 66]. The most attention is drawn to
those photosensitizers which have the maximal absorption pattern shifted to the infrared,
which allows the light to penetrate the tissue deeper and avoids its absorption by melanin. Lab‐
oratory studies also include analyses of mutual influence between molecules of particular pho‐
tosensitizer and melanin. In case of Chlorin e6 and Polyvinylpyrrolidone complex (FOTOLON)
used in our study, research conducted by Parkhots et al. [67] proved that presence of DOPA-
melanin (up to 0.1 mg/ml concentration) does not influence the properties of the photosensitizer
and those systems do not interact with each other, do not form any bonds nor complexes. How‐
ever, even quite low concentration of melanin (up to 0.02 mg/ml) in the sample, despite its lack
of influence on the rate of singlet oxygen creation in the medium, significantly lowers effective‐
ness of that reactive form of oxygen. Other studies which assessed mutual interactions of the
melanin – photosensitizer - light system described occurrence of so called 'side reactions' [68].
Presence of endogeneous chromophores, including melanin, in surface layers of the illuminat‐
ed tissue can significantly limit access of the light (especially that of shorter wavelengths). It
may also result in so called 'photobleaching', which was confirmed for established parameters
of the therapy [68].
First clinical trials with use of PDT in patients with melanoma are currently being conducted.
However, the number of reports with successful application of that kind of therapy is still small.
Due to very limited knowledge of the molecular and long-term effects of such therapy, the most
common but still casuistic reports are related to application of PDT in the palliative therapy of
metastatic melanoma. One such case was described by Fasanell and McGrath [69]. Those re‐
searchers proved effectiveness of the PDT therapy in treatment of melanoma metastasis to the
duodenal ampulla. The therapeutic effect was immediately observed and lasted for a long time
(13 months). Unfortunately, further observation was impossible due to death of the patient
caused probably by metastasis to the brain and complications in a form of the intracerebral hem‐
orrhage. Other cases of PDT application in the available literature concern patients with mela‐
noma of the sight apparatus, lesions in the nasal area and sensitive parts of the face. There are
also reports of successfully concluded therapies of iris melanoma [70], as well as descriptions of
14 patients with metastatic melanoma (13 of them previously treated with other methods) in
which cases a successful elimination of all neoplastic cells was achieved after one treatment
with PDT-chlorin e6 (in 8 cases) or after a series of therapeutic procedures (in 6 cases) [71].
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3. Metalloproteinases in photodynamic therapy of melanoma
Photodynamic therapy (PDT) allows for selective elimination of pathological cells with use of
light. The light illuminates chosen, mostly pathological, cells of the tissue which gathers photo‐
sensitizing substances. The cause of death of those cells are molecular changes that occur during
the therapy. However, a question arises: if use of sublethal conditions (that depend on suscepti‐
bility of cells, their type, concentration of the photosensitizer, presence of oxygen or dose of ra‐
diation) does not increase resistance of the pathological cells to those conditions, leading to
occurrence of a malignant phenotype and, in that way, increasing the possibility of metastasis.
More and more studies describe a co-relation between the degree of invasiveness of neoplastic
cells and changes in expression of metalloproteinases (MMPs) ECM and their inhibitors (TIMs)
located in both neoplastic cells and cells of the stroma - connective tissue of the tumour. Due
to that, an attempt to assess influence of photodynamic therapy on changes in expression of
chosen meta metalloproteinases MMP-2, MMP-9, MMP-14 and their inhibitors TIMP-1 and
TIMP-2 was made in two cultures of melanoma: Colo-829 (melanotic type – a line taken from
cells isolated from skin) and SH-4 (melanotic metastatic type – a line taken from cells isolated
from pleural effusion; initial occurrence - skin; metastatic occurrence – lungs). The influence
of photodynamic therapy on expression of chosen metalloproteinases and their inhibitors was
analysed in melanoma cell cultures and regular fibroblast cultures (HFF-1 line – normal
fibroblasts isolated from skin), the latter were exposed to factors secreted by melanoma cells
after photodynamic therapy.
Chlorin e6 – PVP (Fotolon OAO; producer: Biełmedpreparaty) was used as a photosensitizer
with concentration of 0.01 mg/ml of the growth medium. The photosensitizer was added to
the growth medium in which cultures of a given cell line were grown. After the growth
medium and the photosensitizer were added and an incubation period of 1 hour, cell cultures
were illuminated with use of PDT-662 laser (Kriomed) with a wavelength of 662 nm in 5J, 10J
and 20 J/cm2 doses.
The analysis of chosen genes was carried out at the transcription stage with use of quantitative
determination and QRT-PCR method. Determination of mRNA transcripts of the examined
genes in whole-cell RNA extracts was conducted with use of a DNA Engine OPTICON™
fluorescence detector (MJ Research). After each amplification cycle, the number of PCR
amplicons was determined based on the intensity of SYBR Green I fluorescent dye which binds
to double-stranded DNA, a product of RT-PCR reaction, which has an ability to emit fluores‐
cent light. In order to prepare the reacting QRT-PCR mixture, a stock QuantiTect Sybr Green
RT-PCR Reagent Kit (Qiagen) was used. Amplimer identification was based on electrophoretic
separation in 8% solution of silver-stained polyacrylamide gel.
Specificity of RT-PCR reaction was confirmed for each analysed sample on the basis of a
thermal denaturation profile of the amplification product. The denaturation curve was
established for a range of temperature between 50°C and 95°C. Rapid decrease in intensity of
fluorescence was observed during denaturation of samples at the melting temperature (Tm)
of the amplimer which was contained in that gene. This is due to the release of SYBR Green I
dye from the double-stranded product of the PCR reaction.
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The results of our study, representing a quantitative feature, were checked for normality by
the Shapiro−Wilk test for each trial. In all cases, there was no reason to reject the hypothesis of
normality. Thus, to verify the research hypothesis, parametric tests were used and the data is
expressed as mean values ± standard deviations. Average results of two samples (trials) were
compared using Student's t-test when the assumption of variance homogeneity was met, or
Student's t-test with separate estimation of variance in case of the opposite situation. The
homogeneity of variance for two samples (trials) was checked using Snedecor’s F-test or
Levene's test. Comparison of the average of one distinguished group (control) with the
remaining experimental averages was made using Dunnett's test, after previously determining
(by means of the F-test in variance analysis) the statistical significance of differences between
analysed averages. When comparing the averages of at least three samples (trials), analysis of
variance (ANOVA) was performed. The results for p < 0.05 were considered statistically
significant. Statistica PL version 8 software was used for the statistical analysis.
The results of the study showed expression of mRNA in MMP-2, MMP-9 (on a very low level),
as well as MMP-14 and TIMP-2 of SH-4 metastatic melanoma cells. Only MMP9 and TIMP-2
transcripts were detected in Colo-829 melanoma cells (Table 1).
Melanoma cell
line
MMP-2 [mRNA
copy
number/1 μg
of total RNA]
MMP-9 [mRNA
copy number/1
μg of total
RNA]
MMP-14
[mRNA copy
number/1 μg
of total RNA]
TIMP-1 [mRNA
copy number/1
μg of total
RNA]
TIMP-2 [mRNA
copy number/1
μg of total
RNA]
β-aktyna [mRNA
copy
number1/μg of
total RNA]
Colo-829 - 527 - - 47255 3922322
SH-4 860 57 558459 - 1855586 12604750
Table 1. The mRNA copy number of β-actin, MMP-2, MMP-9, MMP-14 and TIMP-1 and TIMP-2 in melanoma cultures
estimated by QRT-PCT method.
However,  the  results  that  show  limited  expression  of  MMPs  in  in  vitro  melanoma  cell
cultures  are  not  surprising.  It  was  even  suggested  that  neoplastic  cells  themselves  do
not  produce  all  proteolytic  enzymes  necessary  to  initiate  the  invasion  and  metastasis
[72-74].  Some  of  those  enzymes  are  probably  produced  exclusively  by  stimulated  stro‐
ma  cells  [60].  For  example,  Wandel  et  al.  [60]  proved  lack  of  MMP-1  expression  in  in
vitro  melanoma  cell  culture  lines  derived  from  the  primary  tumour  and  the  following
lines:  A365,  SK-Mel-13  and MeWo.  Whereas  Roomi  et  al.  [ADD CITATION]  confirmed
that  some MMP-2  and -9  expression  cannot  be  observed in  some in  vitro  types  of  car‐
cinoma cells.  However,  Hofmann et  al.  [55]  examined changes in  expression of  mRNA,
MMP-1,  -2,  -3,  -9  metalloproteinases  and  TIMP-1  and  -2  inhibitors  in  a  human  model
of  in  vitro  and  in  vivo  melanoma  xenograft.  The  xenograft  comprised  eight  melanoma
cell  lines  with  various  intensity  of  maliciousness.  Those  experiments  proved  that
mRNA  level  expression  of  MMP1  occurred  in  all  melanoma  cell  lines.  However,  pro‐
tein-level  expression  analysed  with  Northern  Blot  method  could  not  be  confirmed
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which  may  suggest  that  the  amount  of  MMP-1  in  those  cells  was  very  small  [55].
Presence  of  mRNA  and  MMP-2  protein  was  confirmed  in  all  cell  lines,  however  the
highest  level  of  expression,  both  in  latent  and  active  MMP-2  form  was  identified  in
the cells  with the  most  malicious phenotype,  those which were  able  to  create  metastat‐
ic  foci  –  MV3  and  BLM  [55].  Presence  of  MMP3  transcripts  was  confirmed  only  in
three  lines:  in  both  most  malicious  (MV3  and  BLM)  and  in  the  cell  line  530,  which
did  not  have  metastatic  features.  However,  presence  of  MMP-3  protein  characterized
only  MV3  and  BLM  lines.  None  of  studied  melanoma  cell  lines  showed  MMP-9  ex‐
pression,  yet  mRNA  and  TIMP-1  and  -2  protiens  were  identified  in  all  of  them  [55].
Therefore,  it  seems  that  only  the  most  aggressive  melanoma  cell  lines  demonstrate  in
vitro  expression of  most  metalloproteinases,  which determine their  invasive abilities.
Results  of  the  research  for  MMP-2,  MMP-9  and  MMP-14  mRNA,  as  well  as  TIMP-1
and TIMP-2  in  SH-4  melanoma cells  are  shown in  Table  1.  They  can  confirm high  in‐
vasiveness of  those cells.
Photodynamic  reaction  conducted  in  Colo-829  and  SH-4  melanoma  cell  lines  with  use
of  Fotolon  causes  inhibition  of  expression  on  the  mRNA  level  for  those  metalloprotei‐
nases  identified  above  or  at  least  significantly  decreases  its  value.  It  makes  further
analysis  of  influence  of  therapeutic  conditions  on  expression  of  chosen  MMPs  and
TIMPs  in  examined in  vitro  melanoma cell  lines  impossible  and focuses the researchers'
attention  on  fibroblasts  stimulated  with  a  growth  media  derived  from  melanoma  cell
cultures  treated  with  PDT.  For  it  has  been  confirmed  that  the  invasive  and  metastatic
processes  occurring  in  tumours  are  results  of  ECM  destruction  caused  by  MMPs,
which  are  produced  by  both  melanoma  and  stroma  cells.  Neoplastic  cells,  due  to  se‐
cretion  of  various  factors,  such  as  growth  factors  and  cytokines,  can  stimulate  neigh‐
bouring  fibroblasts,  which  form  the  stroma  tissue  of  the  tumour,  to  produce  and
change  the  level  of  expression  of  metalloproteinases  [73].  Moreover,  results  of  various
studies  suggest  even that  neoplastic  cells  themselves  do not  produce  all  proteolytic  en‐
zymes necessary to  initiate  the  invasion and metastasis  [72-74].  Some of  those  enzymes
are  probably  produced only  by  stimulated  stroma cells  [60].  Wandel  et  al.  [60]  proved
that  fibroblasts  gathered  around  the  melanoma  cells  have  an  increased  level  of  MMP1
expression  in  comparison  to  those  fibroblasts  which  have  no  contact  with  neoplastic
cells.  Stimulation  of  the  fibroblasts  who did  not  have  any  contact  with  neoplastic  cells
with  the  growth medium gathered from melanoma cell  cultures  leads  to  over  20  times
higher  number  of  MMP1  transcripts  when compared to  unstimulated fibroblasts.  Those
have only three  times higher  level  of  expression when compared to  rhe SK-Mel-13 line
melanoma  cells.  Increase  of  MMP1  expression  was  also  observed  on  the  protein  level.
Wandel  et  al.  [60]  proved  statistically  significant  amounts  of  proteins  between  the  un‐
stimulated  fibroblast  cultures  and  those  cultures  which  were  stimulated  with  the
growth  medium  gathered  from  melanoma  cell  cultures.  Moreover,  Zhang  et  al.  [74]
proved  that  MMP-2  and  MMP-14  (MT1-MMP)  metalloproteinases  produced  by  fibro‐
blasts  attribute to higher invasiveness of  in  vitro  HNSCC tumour (Head and Neck Squ‐
amous Cell  Carcinoma) and stimulate  its  in  vivo  growth.
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Figure 1. Comparison of (A) β-actin, (B) MMP-2, (C) MMP-9, (D) MMP-14, (E) TIMP-1, and (F) TIMP-2 gene expression
at transcription level among fibroblast cultures HFF-1 stimulated with medium from above melanoma cultures from
Colo-829 and SH-4 cell lines before and after PDT. The first and the second column (column I and II) show the changes
of all chosen genes expression in the fibroblast cultures HFF-1 stimulated with medium from above melanoma cul‐
tures from appropriately Colo 829 and SH-2 cell lines. The statistically significant results are marked with the symbol
„*“ (p<0,05).
Results obtained for MMP-2, MMP-9 and MMP-14 metalloproteinases and their TIMP-1 and
TIMP-9 inhibitors confirm processes observed in SK-Mel-13 melanoma line [60], including the
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influence of factors secreted by melanoma cells on expression of metalloproteinases (at the
mRNA level) and their inhibitors by fibroblast cells in in vitro conditions. The conducted re‐
search showed general growth of MMP-2 and MMP-14 metalloproteinase transcripts, as well as
TIMP-2 inhibitor, in fibroblast cells stimulated by the growth medium gathered from both Co‐
lo-829 and SH-4 melanoma cultures. However, statistical significance of the growth of expres‐
sion on the mRNA level occurs only in the case of TIMP-2 in fibroblast cultures stimulated by the
growth medium gathered from Colo-829 (HFF-1/Colo-829) melanoma cultures (p < 0.05). In
case of fibroblast cultures stimulated by the growth medium gathered from Colo-829 (HFF-1/
Colo-829) and SH-4 (HFF-1/SH-4) cultures, a statistically significant decrease of the number of
MMP-9 metalloproteinase transcripts was also observed (p < 0.05). In most cases and independ‐
ently from the applied radiation dose (5 J/cm2, 10 J/cm2 and 20 J/cm2), stimulation of in vitro fibro‐
blasts by the growth medium gathered from the melanoma cell cultures which were treated
with PDT laser in presence of a photosensitizer causes a decrease of expression on the mRNA
level in the examined MMPs and TIMPs in a statistically significant way (p < 0.05) (Fig. 1).
Moreover, in case of normal fibroblast cultures stimulated with the growth medium gathered
from Colo-829 melanoma cell cultures that were previously treated with PDT, an increase of
the ratio between the number of MMP2/TIMP2/MMP14 transcript copies can be observed
when compared to HFF-1/Colo-829 cultures (Table 2, Fig.2).
Stimulated fibroblast cell cultures HFF-1
The proportion of mRNA copy number:
MMP-2 : MMP-14 : TIMP-2
Interaction between the
MMP-14:TIMP-2 proportion
HFF-1 (nonstimulated control cell culture) 1 : 3 : 11 -
HFF-1/Colo-829 1 : 3 : 16
p = 0,0038
HFF-1/Colo-829 F 1 : 3 : 19
HFF-1/Colo-829 5J/cm2 1 : 4 : 14
p = 0,6450
HFF-1/Colo-829 F+5J/cm2 (PDT) 1 : 4 : 13
HFF-1/Colo-829 10J/cm2 1 : 3 : 10
p = 0,1832
HFF-1/Colo-829 F+10J/cm2 (PDT) 1 : 2 : 10
HFF-1/Colo-829 20J/cm2 1 : 29 : 15
p < 0,0001
HFF-1/Colo-829 F+20J/cm2 (PDT) 4 : 1 : 11
HFF-1/SH-4 1 : 4 : 21
p = 0,0086
HFF-1/SH-4 F 1 : 1 : 34
HFF-1/SH-4 5J/cm2 1 : 4 : 27
p < 0,0001
HFF-1/SH-4 F+5J/cm2 (PDT) 1 : 3 : 53
HFF-1/SH-4 10J/cm2 1 : 4 : 22
p = 0,0060
HFF-1/SH-4 F+10J/cm2 (PDT) 1 : 2 : 42
HFF-1/SH-4 20J/cm2 1 : 2 : 19
p = 0,8270
HFF-1/SH-4 F+20J/cm2 (PDT) 1 : 1 : 19
Table 2. The comparition of the proportion of mRNA copy number of MMP-2, MMP-14 and TIMP-2
(MMP-2:MMP-14:TIMP-2) in the fibroblast cell cultures HFF-1 stimulated with media from above melanoma cultures
from Colo 829 and SH-4 cell lines before and after PDT. The table shows also the interaction between the
MMP-14:TIMP-2 proportion in case of pairs of the cell lines: with and without the Photolon (F) addition (the
statistically significant results – interactions - are when p<0,05).
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Figure 2. Comparison of the MMP-2/MMP-14/TIMP-2 mRNA copy number ratio among fibroblast cultures HFF-1
stimulated with media from above melanoma cultures from Colo 829 and SH-4 cell lines before and after PDT. The
statistically significant results are marked with the symbol „*“ (p<0,05).
Appropriate ratio of MMP2/TIMP2/MMP14 gene transcripts guarantees correct course of
MMP-2 activation. Increased MMP-14 expression causes activation of MMP-2 on the surface
of melanoma cells. Activity of MMP-2 is also regulated by presence of TIMP-2. On the one
hand, that inhibitor can influence MMP-2 and, in that way, limit growth of the tumour and
invasiveness. On the other hand, TIMP-2 may be engaged in a direct way in activation of
MMP-2 by forming a complex with MMP-14, which is a receptor for MMP-2 on the surface of
cells. Therefore, only coordinated expression of MMP-2, MMP-14 and TIMP-2 causes activa‐
tion of MMP-2 [50, 55].
It was also observed during gene tagging that a statistically significant decrease in the number
of transcripts of examined genes (p < 0.05) in fibroblasts occurred due to stimulation with the
growth medium gathered from those melanoma cell cultures which were not treated with PDT
but had a photosensitizer added to them. Therefore, Fotolon alone probably causes so
significant changes in synthesis and secretion of factors produced by neoplastic cells and later
present in the growth medium that it also influences expression of MMP genes and fibroblast
TIMPs (Fig. 1).
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The research of expression of MMP-2, MMP-9 and MMP-14, as well as TIMP-1 and TIMP-2 in
Colo-829 and SH-4 melanoma cells conducted and described in our study proves that in
vitro photodynamic therapy of melanoma can cause changes in expression of MMPs and
TIMPs. This may not happen in the melanoma cells themselves but certainly occurs in the
connective stroma tissue of the tumour. Moreover, melanoma cells proved to be sensitive to
both laser light and the photosensitizer alone.
The analysed ratio of MMP/TIMP copies is also significant, as it may influence later synthesis
of proteins and effective activation of metalloproteinases. In most cases, the ratio decreases,
which is particularly noticeable in case of cells stimulated with the growth medium from
Colo-829. Due to the characteristics of TIMPs, it seems that the equilibrium between the level
of active MMPs and their inhibitors may be a turning point in neoplastic progression. As
noticed in the literature [50], overexpression of TIMP-1, TIMP-2 and TIMP-3 may be the cause
of both inhibition of proteolysis and invasion of melanoma. However, in situ research proved
that induction of TIMP-1 and -3, which occurs in a late stage of progression of melanocytic
tumours, is mainly a result of a complex interaction within the MMP/TIMP system. Therefore,
increased expression of TIMPs may inhibit the metastatic process, at the same time giving a
bad prognosis [50, 59].
Demonstrated results of the study are related to the influence of PDT therapy on in vitro
melanoma cultures. Unfortunately, this does not allow for a direct transfer of the observed
processes into in vivo conditions. Therefore, those results cannot be the only premise to forecast
changes of the phenotype in various types of melanoma cells treated with PDT in in vivo
conditions, as the observed changes in parameters that describe the invasive potential of the
tumour do not have to be related only to the speed of its growth and in vivo metastasis [74]. In
order to understand better the influence that photodynamic therapy has on melanoma cells
and the mechanisms triggered by the influence of laser light and a photosensitizer, it is
necessary to conduct further, more detailed research. It is certain that changes of expression
of MMPs and TIMPs on the protein level have to be examined in more detail. It is possible that
other than mentioned in this study MMPs and TIMPs may influence the studied processes,
depending on a type of melanoma in question. Moreover, the research needs to be conducted
in both in vitro and in vivo conditions. Only after such extended amount of data is collected, a
more detailed analysis and comparison of influence of PDT parameters can give a picture of
effectiveness and safety of that kind of therapy on melanoma tumour cases.
4. Summary
Changes in transcriptional activity of MMP2, MMP9, MMP14 genes, as well as TIMP1 and
TIMP2, in Colo-829 and SH-4 lines of cell cultures suggest that photodynamic therapy does
not contribute to an increase of invasiveness of melanoma cells in relation to proteolytic
enzymes of the extracellular matrix, even in sublethal conditions.
However, it should be noted that:
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• presented results of MMP2, MMP9, MMP14, as well as TIMP1 and TIMP2 expression are
related only to the first stage of expression of examined genes (transcription), while the final
effect (which is the amount of active form of enzyme proteins coded by those genes) also
depends on a number of other factors,
• obtained data is valid for cells cultured in in vitro conditions, therefore, in order to formulate
an explicit conclusion as to harmlessness of photodynamic therapy in relation to invasive‐
ness of melanoma cells treated with PDT, this study should be treated as a starting point
and similar research should be conducted in in vivo conditions.
Acknowledgements
This work was supported by a grant sponsored by Statutory Funds of the Medical University
of Silesia (KNW-1-034/10) supported by the Polish Ministry of Science and Higher Education.
Author details
Aleksandra Zielińska, Małgorzata Latocha, Magdalena Jurzak and Dariusz Kuśmierz
Medical University of Silesia, Department of Cell Biology, Poland
References
[1] Curran S, Murray GI. Matrix metalloproteinases in tumor invasion and metastasis.
Review article. Pathology 1999; 189: 300-308.
[2] Dziankowska-Bartkowiak B, Waszczykowska E, Żebrowska A. Udział metaloprotei‐
naz i ich inhibitorów w patomechanizmie wybranych chorób skóry. Alerg Astma Im‐
mun 2004; 9: 71-79.
[3] Wideł MS, Wideł M. Mechanizmy przerzutowania i molekularne markery progresji
nowotworów złośliwych. I. Rak jelita grubego. Post Hig Med Dośw 2006; 60: 453-470.
[4] Chaussain-Miller C, Fioretti F, Goldberg M, Menashi S. The role of matrix Metallo‐
proteinases (MMPs) in human caries. J Dent Res 2006; 85: 22-32.
[5] Bogaczewicz J, Jasielski P, Mosiewicz A, Trojanowski T, Suchożebrska-Jesionek D,
Stryjecka-Zimmer M. Rola metaloproteaz macierzy i tkankowych inhibitorów metal‐
oproteaz w inwazji nowotworów pochodzenia neuroepitelialnego. Neurol Neurochir
Pol 2006; 40: 404-412.
Melanoma - From Early Detection to Treatment / Book 216
[6] Żebrowska A, Bogdańska M, Waszczykowska E. Metaloproteinazy i adamalizyny w
patomechanizmie pemfigoidu. Post Dermatol Alergol 2005; 22: 283-287.
[7] Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer pro‐
gression. Nat Rev 2000; 2: 161-174.
[8] Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macro‐
phage metalloelastase gene expression in colorectal carcinoma and its clinicopatho‐
logic significance. Cancer 2201; 91: 1277-1283.
[9] Takeha, S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of
MMP-9 and urokinase receptor is inversely associated with liver metastasis and with
infiltrating growth in human colorectal cancer: a novel approach from immune/
inflammatory aspect. Jpn J Cancer Res 1997; 88: 72-81.
[10] Jiang, Y, Wang M, Celiker MY, et al. Stimulation of mammary tumorigenesis by sys‐
temic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001;
61: 2365-2370.
[11] Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity
of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107: 2373-2379.
[12] Yoshiji H, Harris SR, Raso E, et al. Mammary carcinoma cells over-expressing tissue
inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor
expression. Int J Cancer 1998; 75: 81-87.
[13] Wang Z, Juttermann, R, Soloway PD. TIMP-2 is required for efficient activation of
proMMP-2 in vivo. J Biol Chem 2000; 275: 26411-26415.
[14] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch
during tumorigenesis. Cell 1996; 86: 353-364.
[15] Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in
mammalian development. Science 1998; 282: 1281-1284.
[16] Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The avb6 integrin promotes prolif‐
eration of colon carcinoma. The avb6 integrin promotes proliferation of colon carci‐
noma. J Cell Biol 1994; 127: 547-556.
[17] Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial cell
apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1
transgene. J Cell Biol 1996; 135: 1669-1677.
[18] Witty JP, Lempka T, Coffey R.J Jr, Matrisian LM. Decreased tumor formation in 7,12-
dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with al‐
terations in mammary epithelial cell apoptosis. Cancer Res 1995; 55: 1401-1406.
[19] Sympson CJ. Talhouk RS, Alexander CM, et al. Targeted expression of stromelysin-1
in mammary gland provides evidence for a role of proteinases in branching morpho‐
Expression of Matrix Metalloproteinases and Theirs Tissue Inhibitors in Fibroblast Cultures and Colo-829 and… 17
genesis and the requirement for an intact basement membrane for tissue – specific
gene expression. J Cell Biol 1994; 125: 681-693.
[20] Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloprotei‐
nase matrilysin proteolytically generates active soluble Fas ligand and potentiates
epithelial cell apoptosis. Curr Biol 1999; 9: 1441-1447.
[21] Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloprotei‐
nase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic
drug cytotoxicity. Cancer Res 2001; 61: 577–581.
[22] Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. CD44 anchors the assembly of
matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and
ErbB4 and regulates female reproductive organ remodeling. Genes Dev 2002; 16:
307-323.
[23] Mañes S. Mira E, del Mar Barbacid M, et al. Identification of insulin-like growth fac‐
tor – binding protein-1 as a potential physiological substrate for human stromely‐
sin-3. J Biol Chem 1997; 272: 25706-25712.
[24] Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene
2000; 19: 5574-5581.
[25] Herren B, Levkau B, Raines EW, Ross R. Cleavage of β-catenin and plakoglobin and
shedding of VE-cadherin during endothelial apoptosis: evidence for a role for cas‐
pases and metalloproteinases. Mol Biol Cell 1998; 9: 1589-1601.
[26] Ilan N, Mohsenin A, Cheung L, Madri JA. PECAM-1 shedding during apoptosis gen‐
erates a membrane – anchored truncated molecule with unique signaling characteris‐
tics. FASEB J 2001; 15: 362-372.
[27] Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O, et al. Cleavage
and shedding of E-cadherin after induction of apoptosis. J Biol Chem 2001; 276:
4972-4980.
[28] Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppress‐
es spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9
and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA
2001; 98: 12485-12490.
[29] Netzer KO, Suzuki K, Itoh Y, Hudson BG, Khalifah RG. Comparative analysis of the
noncollagenous NC1 domain of type IV collagen: identification of structural features
important for assembly, function, and pathogenesis. Protein Sci 1998; 7: 1340-1351.
[30] Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within col‐
lagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;
154: 1069-1080.
Melanoma - From Early Detection to Treatment / Book 218
[31] Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the an‐
giogenic switch during carcinogenesis. Nature Cell Biol 2000; 2: 737-744.
[32] Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane
type 1-matrix metalloproteinase is activated during migration of human endothelial
cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001;
276: 37491-37500.
[33] Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regu‐
late neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-377.
[34] Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate an‐
giostatin: effects on neovascularization. J Immunol 1998; 161: 6845-6852.
[35] Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation
of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-251.
[36] O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angio‐
genesis and tumor growth. Cell 1997; 88: 277-285.
[37] Kim YM. Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular
invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
Cancer Res 2000; 60: 5410-5413.
[38] Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen
activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin ma‐
trices. Blood 2001; 97: 3123-3131.
[39] Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface
provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13:
35-48.
[40] Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin frag‐
ment by matrilysin and stromelysin-1. J Cell Sci 2001; 114: 111-118.
[41] Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial – mesenchymal transitions in
cancer progression. Acta Anat Basel 1996; 156, 217-226.
[42] Nakahara H, Howard L, Thompson EW, et al. Transmembrane/cytoplasmic domain-
mediated membrane type 1-matrix metalloprotease docking to invadopodia is re‐
quired for cell invasion. Proc Natl Acad Sci USA 1997; 94: 7959-7964.
[43] Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer
cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell
1998; 94: 353-362.
[44] Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med
2001; 193: F23-26.
Expression of Matrix Metalloproteinases and Theirs Tissue Inhibitors in Fibroblast Cultures and Colo-829 and… 19
[45] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytical‐
ly activates TGF-band promotes tumor invasion and angiogenesis. Genes Dev 2000;
14: 163-176.
[46] Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade
of transforming growth factor-b signaling in T cells. Nature Med 2001; 7: 1118-1122.
[47] Opdenakker G. Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier
of immune functions. Trends Immunol 2001; 22: 571-579.
[48] McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inacti‐
vates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276:
43503-43508.
[49] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast can‐
cer metastasis. Nature 2001; 410: 50-56.
[50] Hofmann UB, Houben R, Bröcker EB, Becker JC. Role of matrix metalloproteinases in
melanoma cell invasion. Biochimie 2005; 87: 307-314.
[51] Durko M, Navab R, Shibata HR, Brodt P. Suppression of basement membrane type
IV collagen degradation and cell invasion in human melanoma cells expressing an
antisense RNA for MMP-1. Biochim Biophys Acta 1997; 1356: 271-280.
[52] Hofmann UB, Eggert AAO, Blass K, Bröcker EB, Becker JC. Expression of matrix met‐
alloproteinase in the microenvironment of spontaneous and experimental melanoma
metastases reflects the requirements for tumor formation. Cancer Res 2003; 63:
8221-8225.
[53] Zucker S, Cao J. Measurement of matrix metalloproteinases in serum of patients with
melanoma: snarled in technical pitfalls. Commentary on Nikkola et al., p. 5158. Clin
Cancer Res 2005; 11: 5069-5070.
[54] Vaisanen A, Tuominen H, Kallioienen M, Turpeenniemi-Hujanen T. Matrix metalo‐
proteinase-2 (72kD type IV collagenase) expression occurs in the early stage of hu‐
man melanocytic tumor progression and may have prognostic value. J Pathol 1996;
180: 283-289.
[55] Ray JM, Stetler-Stevenson WG, Gelatinase A activity directly modulates melanoma
cell adhesion and spreading. EMBO J 1995; 14: 908-917.
[56] Kurshat P, Wickenhauser C, Groth W, Kreig T, Mauch C. Identification of activated
matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant
melanoma by in situ zymography. J Pathol 2002; 197: 179-187.
[57] Iida J, Wilhemson K L, Price M A et al. Membrane type-1 matrix metalloproteinase
promotes human melanoma invasion and growth. J Invest Dermatol 2004; 122:
167-176.
[58] van den Oord J J, Paemen L, Opdenakker G, De Wolf-Peeters C. Expression of gelati‐
nase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign
Melanoma - From Early Detection to Treatment / Book 220
and malignant pigment cell lesions of the skin. Short Communication. Am J Pathol
1997; 151: 665-670.
[59] Nikkola J, Vihnen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S.
High expression levels of collagenase-1 and stromelisin-1 correlate with shorter dis‐
ease-free survival in human metastatic melanoma. Int J Cancer 2002; 97: 432-438.
[60] Wandel E, Raschke A, Hildebrandt G, et al. Fibroblasts enhance the invasive capacity
of melanoma cells in vitro. Arch Dermatol Res 2002; 293: 601-608.
[61] Podbielska H, Sieroń A, Stręk W. Diagnostyka i terapia fotodynamiczna. Wrocław:
Wydanie I, 2004.
[62] Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy:
Part one – Photosensitizers, photochemistry and cellular localization. Photodiagnosis
and Photodyn Ther 2004; 1: 279-293.
[63] Kramer-Marek G, Serpa C, Szurko A, et al. Spectroscopic properties and photody‐
namic effects of new lipophilic porphyrin derivatives: Efficacy, localisation and cell
death pathways. J Photochem Photobiol B 2006; 84, 1: 1-14.
[64] Tomečka M, Kolařova H, Džubak P, et al. Assessment of early apoptosis on tumour
cell line G361 after photodynamic therapy. Scripta Med 2005; 78, 4: 205-210.
[65] Pasewicz A, Idziak D, Koloczek J, et al. Pair correlation function analysis of 5-(4-hex‐
adecyloxyphenyl)-10,15,20-tri(4-pyridyl)porphyrin and 5-(4-methoxycarbonylphen‐
yl)-10,15,20-tri(4-pyridyl)porphyrin. J Mol Struct 2008; 875, 1-3: 167-172.
[66] Grinholc M, Szramka B, Olender K, Graczyk A. Bactericidal effect of photodynamic
therapy against methicillin-resistant Staphylococcus aureus strain with the use of
various porphyrin photosensitizers. Acta Biochim Pol 2007; 54, 3: 665-670. on-line at:
[www.actabp.pl].
[67] Wang HM, Jiang JQ, Xiao JH, Gao RL, Lin FY, Liu XY. Porphyrin with amino acid
moieties: A tumor photosensitizer. Chem Biol Interact 2008; 127, 2: 154-158.
[68] Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic Antitumor Effect of
Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic
Therapy. Clin Canc Res 2006; 12: 2568-2574.
[69] Usuda J, Hirata T, Ichinose Set al. Tailor-made approach to photodynamic therapy in
the treatment of cancer based on Bcl-2 photodamage. Int J Oncol 2008; 33, 4: 689-696.
[70] Trichopoulos N, Damato B. Photodynamic therapy for recurrent hyphema after pro‐
ton beam radiotherapy of iris melanoma. Graefes Arch Clin Exp Ophthalmol 2007;
245, 10: 1573-1575.
[71] Sheleg SV, Zhavrid EA, Khodina TV. Photodynamic therapy with chlorin e6 for skin
metastases of melanoma. Photodermatol Photoimmunol Photomed 2004; 20: 21-26.
Expression of Matrix Metalloproteinases and Theirs Tissue Inhibitors in Fibroblast Cultures and Colo-829 and… 21

